Telcon RF Pharmaceutical텔콘RF제약
200230 · KOSDAQ · ₩200230 · 텔콘RF제약
- Market cap
- ₩20B
- Enterprise value
- ₩60B
- P/E
- —
- P/B
- 0.3×
- Dividend yield
- 0.0%
- ROE
- −23.8%
- Net margin
- −28.3%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−81.3% from the high
₩1,700Today: ₩1,990 – ₩2,135₩11,027
Returns
- 1W−5.7%
- 1M−5.5%
- 3M+1.0%
- 6M−62.2%
- YTD−73.0%
- 1Y−75.9%
- Volume today
- 35,340
- 2.0× the 20-day average
- Traded today
- ₩74M
- Listed shares
- 9,482,269
- EPS (12 months)
- −₩1,844
- Earnings yield −89.3%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Normal- BuzzNormalBuzz 52: heavy trading.
- MomentumWeak-5.7% over the last month; the price is below its 20-day average.
- News impactSome1 news items and filings in two weeks; 0 rated high impact, 1 medium.
Signals describe activity, not recommendations. Not financial advice.
Telcon RF Pharmaceutical stock overview
Telcon RF Pharmaceutical (텔콘RF제약, KRX: 200230) is listed on KOSDAQ, in the Biotech & Pharma sector. The company manufactures RF components, mainly connectors and cable assemblies used in wireless communication equipment, and is expanding into optical products, including optical cable assemblies, with a focus on FTTA solutions for 5G base stations and expansion into Southeast Asia such as Vietnam. Its shares closed at ₩2,065 on Oct 26, 2026, down 1.20% on the day, giving it a market value of ₩20B.
Key facts
- Market cap
- ₩20B
- Sector
- Biotech & Pharma
- Latest price change
- −1.20%
- As of
- Oct 26, 2026
- Main business
- The company manufactures RF components, mainly connectors and cable assemblies used in wireless communication equipment, and is expanding into optical products, including optical cable assemblies, with a focus on FTTA solutions for 5G base stations and expansion into Southeast Asia such as Vietnam.
Quick answers about Telcon RF Pharmaceutical
- What does Telcon RF Pharmaceutical do?
- The company manufactures RF components, mainly connectors and cable assemblies used in wireless communication equipment, and is expanding into optical products, including optical cable assemblies, with a focus on FTTA solutions for 5G base stations and expansion into Southeast Asia such as Vietnam. It also operates a pharmaceutical and bio business, with a KGMP liquid-formulation production facility that makes various dosage forms and generates revenue from contract manufacturing, and it invests directly and indirectly through itself and affiliates in drug and bio development.
- What is the market cap of Telcon RF Pharmaceutical?
- The market capitalisation of Telcon RF Pharmaceutical was ₩20B at the close on Oct 26, 2026.
- Who are the largest shareholders of Telcon RF Pharmaceutical?
- According to the latest official filings, the largest reported holders are Evercore Investment Holdings (40.78%, as of Jul 16, 2026); Sangsangin Savings Bank (7.84%, as of Oct 12, 2026); NewOn (7.52%, as of Jul 16, 2026).
- When is the next earnings report from Telcon RF Pharmaceutical?
- Korean companies rarely announce results dates in advance. Based on when Telcon RF Pharmaceutical filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own Telcon RF Pharmaceutical?
- Yes. The National Pension Service held 0.20% of Telcon RF Pharmaceutical shares as of Dec 31, 2020.
Company profile
The company manufactures RF components, mainly connectors and cable assemblies used in wireless communication equipment, and is expanding into optical products, including optical cable assemblies, with a focus on FTTA solutions for 5G base stations and expansion into Southeast Asia such as Vietnam. It also operates a pharmaceutical and bio business, with a KGMP liquid-formulation production facility that makes various dosage forms and generates revenue from contract manufacturing, and it invests directly and indirectly through itself and affiliates in drug and bio development.
Written by AI from the company's latest annual report.
- Korean name
- 텔콘RF제약
- Sector
- Biotech & Pharma
- Themes
- Pharmaceuticals
- CEO
- 김지훈
- Founded
- Jan 1999
- Listed
- Nov 2014
- Listed shares
- 9,482,269
- Fiscal year ends
- Month 12
- Website
- www.telcon.co.kr
Similar companies
- Samsung Biologics207940 · ₩67T₩1,452,000−0.95%
- Celltrion068270 · ₩44T₩190,000−2.26%
- Alteogen196170 · ₩15T₩218,500−2.67%
- Yuhan000100 · ₩6T₩81,700−3.54%
- SK biopharmaceuticals326030 · ₩5.9T₩75,800−1.43%
- HLB028300 · ₩5.2T₩39,250−5.65%
- Hanmi Pharm128940 · ₩4.5T₩352,500−2.49%
- SAM Chun Dang Pharm000250 · ₩4.4T₩188,900−5.17%
Recent filings
See all- Major sales or supply contractOct 26, 2026
- 5%+ holding reportOct 12, 2026
- Major sales or supply contractOct 2, 2026
- Material Matters Report (Decision on Acquisition of Own Convertible Bonds Before Maturity)Sep 29, 2026
- Half-year report (Jun 2026)Aug 14, 2026
Titles in Korean until English translations are added.
Also known as: Telcon RF Pharmaceutical / 텔콘RF제약 / 200230 / KRX:200230
Source: KRX statistical information